Stock market technical analysis forecast | Nasdaq trend research for trading investing | 401k
trading penny stock breakout day investing
Skip Navigation Links
    Home
    •   About US
    Market Activity
    World Indices
    Market Watch
    Customer Service
    Learning Center
    Economic Event
    Login


Join Now




Advertise 2 ۩  Daily market forecast

Hot Penny Stock picks for investing - support resistance research

BBI Blockbuster Inc (BBI)
Sector 
RecommendationsBuy
Buy Near0.76
Stop Loss0.70
Posted Date1/18/2010 12:00:00 AM
First resistance0.92
Second resistance1.03
Third resistance1.38
First Support0.60
Second Support0.62
Comments
1/18/2010 12:00:00 AM0) Blockbuster Inc (BBI) is a leading global provider of rental and retail movies and games
1) This penny Stock company (BBI) provides customers with convenient access to media entertainment anywhere, any way they want it - whether in-store, by-mail, through vending kiosks or digitally downloaded directly to their family room or mobile device
2) Blockbuster Inc (BBI) have library of more than 125,000 movies and games
3) Blockbuster Inc (BBI) recently announced that it has eliminated the final $24 million of certain letters of credit it maintained on behalf of its former parent company, Viacom Inc and this stapes naturally increase the liquidity of cash, again Blockbuster Inc (BBI) raised $675 million on our bond offering to extend our debt maturities into 2014

As per technical analysis of this penny Stock ADX and Stockhastic given a buy signal and it Started up trend with RSI positive divergence and recently it breakout with very high volume
4) Recent company’s action also supporting our positive view, so Blockbuster Inc (BBI) you can consider for breakout penny Stock portfolio, and you can enter near $0.76 with $0.60 stop loss
5) This Stock trading with high volume so you can consider for penny Stock day trading also
6)

DM crossover and raising ADX with Stockhastic buy signal and breakout with high volume and sustain breakout point on following day is a ideal condition to buy Stock and in this penny Stock you found all this factors, still keep stop loss because penny Stock when turn negative we never know, so protect your investment stop loss is important
7)
BBI
Brickell Biotech Announces Launch Date for Sofpironium Bromide Gel, 5% (ECCLOCK®) in Japan by its Development Partner, Kaken Pharmaceutical
(Wed, 18 Nov 2020 12:00:00 +0000)
Kaken plans to launch ECCLOCK® for the treatment of primary axillary hyperhidrosis in Japan on November 26, 2020 \- - - ECCLOCK® placed on Japan’s National Health Insurance (NHI) drug reimbursement price listBOULDER, Colo., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that its Japanese development partner, Kaken Pharmaceutical Co., Ltd. (“Kaken”) plans to launch sofpironium bromide gel, 5% under the brand name ECCLOCK® in Japan for the once daily treatment of primary axillary (underarm) hyperhidrosis on November 26, 2020. In addition, ECCLOCK® has been placed today on Japan’s National Health Insurance (NHI) drug reimbursement price list. The NHI listed drug price for ECCLOCK® in Japan is ¥243.70 per gram, which is ¥4,874.00 (USD $46.47) for a 20 gram bottle or approximately a two-week supply.“We are excited to announce the reimbursement and planned commercial launch of ECCLOCK® in Japan, which is the first topical prescription product to be approved and marketed there for the treatment of primary axillary hyperhidrosis,” said Robert Brown, Chief Executive Officer of Brickell. “A key step to Kaken’s moving forward with the planned commercial launch of ECCLOCK® in Japan was their receipt of the reimbursement price listing by the NHI. Kaken is now well-positioned to launch ECCLOCK® in Japan on November 26 as an important novel, first-in-class therapy for the millions of Japanese patients suffering with this debilitating medical condition.”On September 25, 2020, Kaken received approval from the Japanese Pharmaceuticals and Medical Devices Agency to manufacture and market ECCLOCK® for the once-daily treatment of primary axillary hyperhidrosis.Under the sublicense agreement with Kaken, Brickell is entitled to receive sales-based milestone payments, as well as tiered royalties based on a percentage of net sales of ECCLOCK® in Japan. Furthermore, Kaken has rights to develop and commercialize sofpironium bromide in Korea, China and certain other Asian countries.Sofpironium bromide is currently being developed by Brickell in the U.S. for the treatment of primary axillary hyperhidrosis. Brickell recently initiated its pivotal Phase 3 clinical program in the U.S., which is comprised of two pivotal Phase 3 clinical trials (Cardigan I and II) to evaluate the safety and efficacy of sofpironium bromide gel, 15% compared to vehicle (placebo) in approximately 350 subjects (per trial) aged nine years and older with primary axillary hyperhidrosis. Brickell expects to report topline data from both the Cardigan I and II studies in the fourth quarter of 2021.About Sofpironium BromideSofpironium bromide is a proprietary investigational new chemical entity that belongs to a class of medications called anticholinergics. Anticholinergics block the action of acetylcholine, a chemical that transmits signals within the nervous system that are responsible for a range of bodily functions, including activation of the sweat glands. Sofpironium bromide was retrometabolically designed. Retrometabolic drugs are designed to exert their action topically and are potentially rapidly metabolized into a less active metabolite once absorbed into the blood.  Sofpironium bromide was discovered at Bodor Laboratories, Inc. by Dr. Nicholas Bodor D.Sc., d.h.c. (multi), HoF, Graduate Research Professor Emeritus, University of Florida.About HyperhidrosisHyperhidrosis is a life-altering medical condition where a person sweats more than the body requires to regulate its temperature. More than 15 million people, or 4.8% of the population of the United States, and 12.76% of the population in Japan, are believed to suffer from hyperhidrosis1,2. Primary axillary (underarm) hyperhidrosis is the targeted first indication for sofpironium bromide and is the most common site of occurrence of hyperhidrosis, affecting an estimated 65% of patients with hyperhidrosis in the United States. Additional information can be found on the International Hyperhidrosis Society website: https://www.sweathelp.org/.About BrickellBrickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace. For more information, visit https://www.brickellbio.com.Cautionary Note Regarding Forward-Looking StatementsAny statements made in this press release relating to future financial, business and/or research and clinical performance, conditions, plans, prospects, trends, or strategies and other such matters, including without limitation, the anticipated timing, scope, design and/or results of ongoing and future clinical trials, intellectual property rights, including the validity, term and enforceability of such, the expected timing and/or results of regulatory approvals and prospects for commercializing any of Brickell’s product candidates, or research collaborations with, or actions of, its partners, including in Japan, the United States or any other country, are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict,” “potential,” “look forward” and similar expressions and their variants, as they relate to Brickell, Kaken, AnGes or any of Brickell’s partners, may identify forward-looking statements. Brickell cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time, often quickly and in unanticipated ways. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including without limitation, ability to obtain adequate financing to advance product development, ability to maintain and enforce intellectual property rights, potential delays for any reason in product development, regulatory changes, supply chain disruptions, unanticipated demands on cash resources, any disruption to its business caused by the current COVID-19 pandemic, interruptions, disruption or inability by Kaken to supply, launch and commercialize the product in Japan, or obtain or retain adequate pricing or reimbursement, and other risks associated with developing, and obtaining regulatory approval for and commercializing product candidates.Further information on the factors and risks that could cause actual results to differ from any forward-looking statements are contained in Brickell’s filings with the United States Securities and Exchange Commission (SEC), which are available at https://www.sec.gov (or at https://www.brickellbio.com). The forward-looking statements represent the estimates of Brickell as of the date hereof only, and Brickell specifically disclaims any duty or obligation to update forward-looking statements.                                  1Doolittle et al. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res 2016; 308: 743-749. 2 Fujimoto et al. Epidemiological study and considerations of focal hyperhidrosis in Japan. J Dermatol 2013; 40: 886-90.Brickell Investor Contact: Dan Ferry LifeSci Advisors (617) 430-7576 daniel@lifesciadvisors.com
Brickell Biotech to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
(Mon, 16 Nov 2020 13:00:00 +0000)
BOULDER, Colo., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that its management team will participate in the Piper Sandler 32nd Annual Healthcare Conference taking place December 1-3, 2020. Brickell’s Chief Executive Officer, Robert Brown, will present a corporate overview and Brickell’s management team will be available for one-on-one meetings. The pre-recorded presentation will be available on the event website prior to the dates of the conference. A replay of the corporate presentation will be available in the investors section of Brickell’s website at https://ir.brickellbio.com/events-presentations and will remain archived there for approximately 90 days.About Sofpironium BromideSofpironium bromide is a proprietary investigational new chemical entity that belongs to a class of medications called anticholinergics. Anticholinergics block the action of acetylcholine, a chemical that transmits signals within the nervous system that are responsible for a range of bodily functions, including activation of the sweat glands. Sofpironium bromide was retrometabolically designed. Retrometabolic drugs are designed to exert their action topically and are potentially rapidly metabolized into a less active metabolite once absorbed into the blood. Sofpironium bromide is currently being evaluated in a U.S. pivotal Phase 3 clinical program for the treatment of primary axillary hyperhidrosis and is approved (pending launch) in Japan for the same indication, under the brand name ECCLOCK®.  Sofpironium bromide was discovered at Bodor Laboratories, Inc. by Dr. Nicholas Bodor D.Sc., d.h.c. (multi), HoF, Graduate Research Professor Emeritus, University of Florida.About HyperhidrosisHyperhidrosis is a life-altering medical condition where a person sweats more than the body requires to regulate its temperature. More than 15 million people, or 4.8% of the population of the United States, and 12.76% of the population in Japan, are believed to suffer from hyperhidrosis1,2. Primary axillary (underarm) hyperhidrosis is the targeted first indication for sofpironium bromide and is the most common site of occurrence of hyperhidrosis, affecting an estimated 65% of patients with hyperhidrosis in the United States. Additional information can be found on the International Hyperhidrosis Society website: https://www.sweathelp.org/.About BrickellBrickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace. For more information, visit https://www.brickellbio.com.                                1 Doolittle et al. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res 2016; 308: 743-749. 2 Fujimoto et al. Epidemiological study and considerations of focal hyperhidrosis in Japan. J Dermatol 2013; 40: 886-90.Brickell Investor Contact: Dan Ferry LifeSci Advisors (617) 430-7576 daniel@lifesciadvisors.com
Brickell Biotech Reports Third Quarter 2020 Financial Results and Provides Corporate Update
(Thu, 12 Nov 2020 21:01:00 +0000)
Recently completed capital raise expected to fully fund U.S. pivotal Phase 3 program, with topline results anticipated in Q4 2021 \- - - Initiated the Cardigan I study, the first of two U.S. pivotal Phase 3 clinical studies evaluating sofpironium bromide gel, 15% as a potential treatment for primary axillary hyperhidrosis \- - - On track to initiate the Cardigan II study, the second U.S. pivotal Phase 3 clinical study, later this year \- - - Planned commercial launch of ECCLOCK® in Japan by development partner, Kaken, expected by the end of 2020, which follows regulatory approval received in the third quarterBOULDER, Colo., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced financial results for the third quarter ended September 30, 2020 and provided a corporate update.“I am proud of the focus, drive and determination that the Brickell team has shown in 2020, which has allowed us to execute against our corporate goals. As a result, we are now well-positioned to continue executing our strategy to develop sofpironium bromide as a potentially best-in-class treatment option for the more than 10 million people in the U.S. suffering with primary axillary hyperhidrosis,” commented Robert Brown, Chief Executive Officer of Brickell. “Last month, we initiated the Cardigan I registration trial and completed an equity financing, which provided us with additional capital needed to initiate the Cardigan II second registration trial later this year and is expected to allow us to complete the U.S. pivotal Phase 3 program, with topline results anticipated in the fourth quarter of 2021.”“The third quarter was a productive period for our Japanese development partner, Kaken, who recently received regulatory approval for ECCLOCK® (sofpironium bromide gel, 5%) in Japan for the treatment of primary axillary hyperhidrosis. Japan is the first country to approve sofpironium bromide for any indication and Kaken remains on target for commercial launch later this year. We are thrilled with the progress that both Brickell and Kaken have made and look forward to providing updates on the advancement of our U.S. pivotal Phase 3 program, as well as Kaken’s launch efforts in Japan, over the coming months,” concluded Mr. Brown.Business and Recent Developments * Completed an equity financing in October 2020 resulting in net proceeds of approximately $13.7 million that strengthened the Company’s balance sheet and is expected to fully fund its operations through topline results of the U.S. pivotal Phase 3 program. * Initiated the U.S. Phase 3 Cardigan I clinical trial, a multicenter, randomized, double-blinded, vehicle (placebo)-controlled study to evaluate the safety and efficacy of topically applied sofpironium bromide gel, 15% for the treatment of primary axillary (underarm) hyperhidrosis. Subjects will apply sofpironium bromide or vehicle once daily at bedtime to their underarms for six consecutive weeks, with a two-week post-treatment follow-up. The study is expected to enroll up to 350 subjects aged nine years and older with primary axillary hyperhidrosis. * Japanese development partner, Kaken Pharmaceutical, Co., Ltd. (“Kaken”), received regulatory approval in Japan to manufacture and market sofpironium bromide gel, 5% for the treatment of primary axillary hyperhidrosis. This approval was based on the results of Kaken’s Japanese pivotal Phase 3 registration study of sofpironium bromide gel, 5% in 281 patients with primary axillary hyperhidrosis, in which all primary and secondary efficacy endpoints demonstrated statistically significant differences between sofpironium bromide gel and vehicle. In addition, sofpironium bromide gel, 5% was observed to be safe and generally well tolerated in this study, as well as in the accompanying 52-week long-term safety extension study with 185 patients in Japan. * Kaken and Brickell were granted by the Japanese Patent Office a composition of matter patent with claims directed to the novel polymorphic, or crystalline, forms of sofpironium bromide that is expected to provide additional protection for these newly developed and distinct forms in Japan through 2040.  * Completed the 12-month Phase 3 open-label long-term safety study evaluating sofpironium bromide gel, 5% and 15% in 300 subjects nine years and older with primary axillary hyperhidrosis. The study results confirmed that sofpironium bromide gel, at both concentrations, was safe and generally well tolerated, which was consistent with the earlier Phase 2 clinical trial results. No treatment-related serious adverse events were observed. The Company expects to release additional details at an upcoming scientific forum. * Entered into a collaboration agreement with AnGes, Inc (“AnGes”) through which the Company has certain rights to develop AnGes’ proprietary investigational adjuvanted plasmid DNA vaccine intended to prevent SARS-CoV-2 (COVID-19) in the U.S., South America and certain other emerging markets. AnGes is currently conducting Phase 1/2 clinical studies with its vaccine candidate in Japan.Upcoming Milestones * Plan to initiate the Cardigan II study, the second U.S. pivotal Phase 3 clinical trial, prior to year end. The Cardigan II study will evaluate the safety and efficacy of sofpironium bromide gel, 15% versus vehicle in approximately 350 subjects aged nine years and older with primary axillary hyperhidrosis. * Expect Kaken to launch ECCLOCK® commercially in Japan by the end of 2020. Under our agreement with Kaken, Brickell is entitled to receive commercial milestone payments, as well as tiered royalties based on a percentage of net sales in Japan. * Expect to report topline data from both the Cardigan I and II U.S. pivotal Phase 3 clinical studies by the end of 2021. * Expect to receive results from the Phase 1/2 clinical studies with AnGes’ COVID-19 vaccine candidate in Japan through the first quarter of 2021. The results from these studies will guide AnGes’ and Brickell’s global development efforts of this novel vaccine candidate.Financial ResultsThe Company reported cash and cash equivalents and marketable securities of $20.2 million as of September 30, 2020 compared to $11.7 million as of December 31, 2019. In addition, Brickell has prepaid $4.2 million to third-party clinical research organizations as part of conducting the U.S. pivotal Phase 3 clinical trials of sofpironium bromide. Subsequent to the end of the third quarter, the Company completed a public equity offering resulting in net proceeds of approximately $13.7 million.Revenue was $0.1 million for the third quarter of 2020 compared to $1.2 million for the third quarter of 2019. Revenue in both periods was driven by research and development activities related to the agreement with Kaken pursuant to which Kaken provided research and development funding to Brickell. The decrease in revenue recognized was attributable to Brickell’s Phase 3 open-label long-term safety study of sofpironium bromide gel and other ancillary clinical studies that were ongoing in 2019 but were concluded or winding down by the end of the first quarter of 2020. Conducting these studies is the basis for revenue recognition of a $15.6 million research and development payment received from Kaken in the second quarter of 2018.Research and development expenses were $1.3 million for the third quarter of 2020 compared to $3.3 million for the third quarter of 2019. This decrease was primarily due to reduced clinical and other related regulatory and compliance costs of the Phase 3 open-label long-term safety study of sofpironium bromide gel and other ancillary clinical studies that were concluded or winding down by the end of the first quarter of 2020.General and administrative expenses were $3.2 million for the third quarter of 2020 compared to $3.9 million for the third quarter of 2019. This decrease was primarily due to lower costs of $1.1 million for professional-related fees associated with the merger with Vical Incorporated that occurred in the third quarter of 2019 and $0.4 million for other miscellaneous fees, partially offset by higher costs of $0.6 million for stock and other compensation expense that was driven by increased headcount and $0.2 million for directors’ and officers’ liability insurance due to becoming a public company.Brickell’s net loss was $4.3 million for the third quarter of 2020 compared to $4.8 million for the third quarter of 2019.Conference Call and Webcast InformationBrickell’s management will host a conference call today at 4:30 p.m. ET to discuss the financial results and recent corporate developments. The dial-in number for the conference call is 1-877-705-6003 for domestic participants and 1-201-493-6725 for international participants, with Conference ID 13708850. A live webcast of the conference call can be accessed through the “Investors” tab on the Brickell Biotech website at https://www.brickellbio.com. A replay will be available on this website shortly after conclusion of the event for 90 days.About Sofpironium BromideSofpironium bromide is a proprietary investigational new chemical entity that belongs to a class of medications called anticholinergics. Anticholinergics block the action of acetylcholine, a chemical that transmits signals within the nervous system that are responsible for a range of bodily functions, including activation of the sweat glands. Sofpironium bromide was retrometabolically designed. Retrometabolic drugs are designed to exert their action topically and are potentially rapidly metabolized into a less active metabolite once absorbed into the blood. Sofpironium bromide was discovered at Bodor Laboratories, Inc. by Dr. Nicholas Bodor D.Sc., d.h.c. (multi), HoF, Graduate Research Professor Emeritus, University of Florida.About HyperhidrosisHyperhidrosis is a life-altering medical condition where a person sweats more than the body requires to regulate its temperature. More than 15 million people, or 4.8% of the population of the United States, and 12.76% of the population in Japan, are believed to suffer from hyperhidrosis1,2. Primary axillary (underarm) hyperhidrosis is the targeted first indication for sofpironium bromide and is the most common site of occurrence of hyperhidrosis, affecting an estimated 65% of patients with hyperhidrosis in the United States. Additional information can be found on the International Hyperhidrosis Society website: https://www.sweathelp.org/.About BrickellBrickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace. For more information, visit https://www.brickellbio.com. Cautionary Note Regarding Forward-Looking StatementsAny statements made in this press release relating to future financial, business and/or research and clinical performance, conditions, plans, prospects, trends, or strategies and other such matters, including without limitation, the anticipated timing, scope, design and/or results of ongoing and future clinical trials, intellectual property rights, including the validity, term and enforceability of such, the expected timing and/or results of regulatory approvals and prospects for commercializing any of Brickell’s product candidates, or research collaborations with its partners, including in Japan, the United States or any other country, are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict,” “potential,” “look forward” and similar expressions and their variants, as they relate to Brickell, Kaken, AnGes or any of Brickell’s partners, may identify forward-looking statements. Brickell cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time, often quickly and in unanticipated ways. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including without limitation, ability to obtain adequate financing to advance product development, ability to maintain and enforce intellectual property rights, potential delays for any reason in product development, regulatory changes, supply chain disruptions, unanticipated demands on cash resources, any disruption to its business caused by the current COVID-19 pandemic, interruptions, disruption or inability by Kaken to supply, launch and commercialize the product in Japan, or obtain adequate pricing, and other risks associated with developing, and obtaining regulatory approval for and commercializing product candidates.Further information on the factors and risks that could cause actual results to differ from any forward-looking statements are contained in Brickell’s filings with the United States Securities and Exchange Commission (SEC), which are available at https://www.sec.gov (or at https://www.brickellbio.com). The forward-looking statements represent the estimates of Brickell as of the date hereof only, and Brickell specifically disclaims any duty or obligation to update forward-looking statements.                                 1 Doolittle et al. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res 2016; 308: 743-749. 2 Fujimoto et al. Epidemiological study and considerations of focal hyperhidrosis in Japan. J Dermatol 2013; 40: 886-90.Brickell Investor Contact: Dan Ferry LifeSci Advisors (617) 430-7576 daniel@lifesciadvisors.comBrickell Biotech, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (unaudited)     Three Months Ended September 30, Nine Months Ended September 30,   2020 2019 2020  2019   Collaboration revenue $142  $1,183  $1,795  $7,248                    Operating expenses:                 Research and development 1,281  3,337  6,657  13,585  General and administrative 3,211  3,901  8,713  7,290  Total operating expenses 4,492  7,238  15,370  20,875  Loss from operations (4,350) (6,055) (13,575) (13,627) Investment and other income, net 24  54  27  64  Gain on extinguishment —  2,318  —  2,318  Interest expense —  (1,098) —  (1,982)               Change in fair value of warrant and derivative liability —  —  —  212  Net loss (4,326) (4,781) (13,548) (13,015) Reduction (accretion) of redeemable convertible preferred stock to redemption value —  (82) —  10,274  Net loss attributable to common stockholders $(4,326) $(4,863) $(13,548) $(2,741) Net loss per common share attributable to common stockholders, basic and diluted $(0.15) $(1.65) $(0.82) $(1.98) Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted 28,107,785  2,943,896  16,475,843  1,382,592                Brickell Biotech, Inc. Selected Financial Information Condensed Consolidated Balance Sheet Data (amounts in thousands) (unaudited)    September 30, 2020 December 31, 2019 Cash and cash equivalents$20,174  $7,232  Marketable securities, available-for-sale—  4,497  Prepaid expenses and other current assets6,129  6,240  Total assets26,404  18,144  Total liabilities7,692  10,570  Total stockholders’ equity18,712  7,574
Brickell Biotech Inc to Host Earnings Call
(Thu, 12 Nov 2020 19:30:00 +0000)
NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Brickell Biotech Inc (BBI) (NASDAQ:BBI) will be discussing their earnings results in their call to be held on November 12, 2020 at 4:30 PM Eastern Time.
Brickell Biotech to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on November 12, 2020
(Thu, 29 Oct 2020 12:00:00 +0000)
BOULDER, Colo., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will report its financial results for the third quarter ended September 30, 2020, after the market close on Thursday, November 12, 2020. Brickell’s management will host a conference call and webcast at 4:30 pm ET on Thursday, November 12th to discuss the financial results and recent corporate highlights. To access the call, please dial 877-705-6003 in the U.S. or 201-493-6725 outside the U.S. and provide the conference ID number: 13708850. To access the live webcast, please go to the Investors section of Brickell’s website at https://ir.brickellbio.com/events-presentations. Following the live webcast, an archived version of the call will be available on the website.About BrickellBrickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace. For more information, visit https://www.brickellbio.com.Brickell Investor Contact: Dan Ferry LifeSci Advisors (617) 430-7576 daniel@lifesciadvisors.com
HCKT Hackett Group, Inc
SectorServices
RecommendationsBuy
Buy Near2.12
Stop Loss1.88
Posted Date6/6/2009 1:32:46 AM
First resistance3.04
Second resistance3.38
Third resistance5.44
First Support2.00
Second Support1.88
Comments
6/6/2009 3:45:25 PM0) Penny Stock Alert - Hackett Group, Inc
1) (HCKT) is a global strategic advisory firm and company is a leader in best practice advisory, benchmarking, and transformation consulting services, including shared services, outsourcing and off shoring advice
2) Hackett business application consulting services helps costumer to maximize returns on IT investments At the end of the first quarter of 2009, the Hackett Group, Inc
3) (HCKT) got cash balance $26.3 million, and as per company Stock repurchase plan, the Company already repurchased approximately 1.0 million shares at average price $2.08 per share, for a total cost of $2.1 million
4) And still approximately $4.8 million remained available under the Company’s share repurchase program.

Based on the current economic Outlook, the Hackett Group, Inc
5) (HCKT) estimates total revenue for the second quarter of 2009 to be in the range of $34.0 M to $36.0 M and estimates earnings per share to be in the range of $0.00 to $0.03. Recently Wipro Technologies (WIT) announced they partnered with Oracle for best-of-breed HR platform solutions and for that Wipro has also selected The Hackett Group (HCKT), to provide empirical data, best practices and world-class Performance insights on the development of its innovative bundled solution platform
6) The solution, allows employers to reduce and control cost as it provides an opportunity to centralize and standardize processes while eliminating duplicative management structures
7)

As per chart analysis Hackett Group, Inc
8) (HCKT) Relative Strength (RSI) started to strengthening, rate of change also got good moment again there are strong demand closer to $2.12 that indicating accumulation going on, with good capital in hand and suitable to present economy business model offering over all best penny Stock investing option
9)
HCKT
What Do The Returns On Capital At Hackett Group (NASDAQ:HCKT) Tell Us?
(Sat, 14 Nov 2020 14:03:02 +0000)
What are the early trends we should look for to identify a stock that could multiply in value over the long term...
Hackett Group Inc (HCKT) Q3 2020 Earnings Call Transcript
(Tue, 03 Nov 2020 05:01:50 +0000)
Good afternoon, everyone, and thank you for joining us to discuss The Hackett Group's third quarter results. Speaking on the call today and here to answer your questions are Ted Fernandez, Chairman and CEO of The Hackett Group; and myself, Rob Ramirez, Chief Financial Officer.
Hackett Group (HCKT) Tops Q3 Earnings and Revenue Estimates
(Mon, 02 Nov 2020 23:55:11 +0000)
Hackett Group (HCKT) delivered earnings and revenue surprises of 21.43% and 9.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
The Hackett Group: Q3 Earnings Insights
(Mon, 02 Nov 2020 21:36:29 +0000)
Shares of The Hackett Group (NASDAQ:HCKT) moved higher by 1.15% in after-market trading after the company reported Q3 results.Quarterly Results Earnings per share were down 37.04% over the past year to $0.17, which beat the estimate of $0.13.Revenue of $57,917,000 declined by 20.32% year over year, which beat the estimate of $53,140,000.Guidance Earnings guidance hasn't been issued by the company for now.The Hackett Group hasn't issued any revenue guidance for the time being.Details Of The Call Date: Nov 02, 2020View more earnings on HCKTTime: 05:00 PMET Webcast URL: https://www.thehackettgroup.com/Price Action 52-week high: $18.90Company's 52-week low was at $9.50Price action over last quarter: down 2.24%Company Overview The Hackett Group Inc is a United States based advisory firm. The company's offerings include executive advisory programs, benchmarking, business transportation, and technology advisory services. The company's executive and practices advisory programs offer performance metrics, peer-learning opportunities, and practice implementation practices. The benchmarking services help organizations measure and assess internal efficiency and effectiveness. The business transformation programs help customers develop strategies to improve performance. The company's technology advisory services help clients improve decision-making capabilities and deploy software applications. The Hackett Group generates the majority of its revenue in the United States.See more from Benzinga * Click here for options trades from Benzinga * Earnings Scheduled For November 2, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The Hackett Group Announces Third Quarter 2020 Results
(Mon, 02 Nov 2020 21:05:00 +0000)
The Hackett Group Announces Third Quarter 2020 Results
LOJN LO-JACK CORP COM
SectorSecurity Systems & Services
RecommendationsBuy
Buy Near3.84
Stop Loss3.21
Posted Date2/8/2009 12:00:00 AM
First resistance5.33
Second resistance6.73
Third resistance7.20
First Support3.41
Second Support3.21
Comments
2/8/2009 12:42:24 PM0) LoJack Corporation (LOJN), the company that invented the stolen vehicle recovery market more than two decades ago, is the global leader in finding and recovering a wide range of mobile assets including cars, construction equipment and motorcycles having recovered more than $5 billion USD in stolen assets worldwide
1) In today's rapidly changing world, LoJacks core competencies are more valuable and more relevant than ever as they are now being applied into new areas, such as the prevention, detection and recovery of stolen cargo and finding and rescuing people with cognitive disorders such as Alzheimers and autism
2) LoJack has the proven processes, ultimate technology for recovery ,Radio Frequency and unique integration with law enforcement agencies, making its offerings the most effective solutions that not only deliver a wide range of recoveries, but also enhance the safety of the public on a global level
3) LoJacks Stolen Vehicle Recovery System operates in 26 states and the District of Columbia, and in more than 30 countries throughout North America, South America, Europe, Africa and Asia
4) This Penny Stock looks good candidate for portfolio investment
5) Before to invest Penny Stock understand your risk
6) To manage your risk keep tight stop loss on all investment.
LOJN
ANAD ANADIGICS Inc
SectorSemiconductors
RecommendationsBuy
Buy Near2.16
Stop Loss1.90
Posted Date2/8/2009 12:00:00 AM
First resistance2.55
Second resistance3.06
Third resistance3.92
First Support2.16
Second Support1.90
Comments
2/8/2009 12:45:38 PM0) ANADIGICS, Inc
1) is a provider of semiconductor solutions in the broadband wireless and wire line communications markets
2) The Company’s products include power amplifiers (PAs), tuner integrated circuits, active splitters, line amplifiers and other components, which can be sold individually or packaged as integrated radio frequency (RF) and front end modules This penny Stock closer to its strong support and looks good candidate for portfolio investment
3) Before to invest in penny Stock understand the risk factor
4) Due to market and economic condition keep tight stop loss on all investment.
ANAD
CHUX O CHARLEYS INC COM
SectorRestaurants
RecommendationsBuy
Buy Near2.66
Stop Loss1.96
Posted Date2/8/2009 12:00:00 AM
First resistance3.14
Second resistance5.44
Third resistance7.30
First Support2.05
Second Support1.23
Comments
2/8/2009 12:50:26 PM0) OCharleys Inc
1) is a casual dining restaurant company
2) The Company owns and operates three restaurant concepts under the OCharleys, Ninety Nine and Stony River Legendary Steaks trade names
3) As of December 30, 2007, it operated 229 OCharleys company owned restaurants in 16 states in the Southeast and Midwest, 115 Ninety Nine restaurants in nine Northeastern states, and ten Stony River restaurants in six states in the Southeast and Midwest OCharleys beats by $0.13, misses on revs Reports Q4 (Dec) loss of $0.15 per share, $0.13 better than the First Call consensus of ($0.28); revenues fell 5.7% year/year to $202.9 mln vs the $206.8 mln consensus The main difference here is that OCharleys would have still closed out its latest quarter in the red without writing down the value of its assets
4) This penny Stock closer to its strong support and looks good candidate for portfolio investment
5) Before to invest in any penny Stock understand your risk
6)
CHUX
ACTG Acacia Research Corporation
SectorTechnology : Electronic Instr. & Controls
RecommendationsBuy
Buy Near3.01
Stop Loss2.42
Posted Date1/1/2009 12:00:00 AM
First resistance3.61
Second resistance4.60
Third resistance5.55
First Support3.01
Second Support2.84
Comments
1/1/2009 8:55:19 PM0) Acacia Research Corporation (ACTG) has given a breakout with high volume and also given a buy signal, with rising moving average
1) Stockhastic, rate of change (ROC) and ADX also given a buy signal Acacia Research Corporation (ACTG) announced on Dec 31 2008 that its subsidiary, Data Network Storage LLC, Telematics Corporation, International Printer Corporation and Light Valve Solutions LLC has entered into a settlement and license agreement with the Hewlett-Packard Company relates to storage area networks, Datatrac Corporation, Océ, N.V
2) and Océ North America, Inc
3) and Hitachi, Ltd respectively
4) Recently Acacia Research Corporation (ACTG) bought the rights to a patent related to wireless data technology and its subsidiary, Acacia Patent Acquisition LLC, has acquired the rights to patents relating to vehicle occupant sensing technology.

As per technical analysis and fundamental research Acacia Research Corporation (ACTG) looks good candidate for penny Stock investing as well as you can add in portfolio investment
5) Recently ACTG given a breakout with rising moving average and also Stockhastic and Rate of change (ROC) given a buy signal
6) Acacia Research Corporation (ACTG) you can consider for Investment, Swing Trading, penny Stock Investing, Day trading
7) Due to market and economic condition keep tight stop loss on all position
8) You can buy Acacia Research Corporation (ACTG) near $3.01
ACTG
Acacia Research Corp. to Host Earnings Call
(Mon, 09 Nov 2020 14:30:00 +0000)
NEW YORK, NY / ACCESSWIRE / November 9, 2020 / Acacia Research Corp.
Acacia Research: Q3 Earnings Insights
(Mon, 09 Nov 2020 13:49:15 +0000)
Shares of Acacia Research (NASDAQ:ACTG) remained unaffected after the company reported Q3 results.Quarterly Results Earnings per share rose 313.33% year over year to $0.32, which beat the estimate of ($0.02).Revenue of $19,466,000 rose by 1037.70% year over year, which beat the estimate of $400,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: Nov 09, 2020View more earnings on ACTGTime: 11:00 AMET Webcast URL: https://www.webcaster4.com/Webcast/Page/2371/38302Recent Stock Performance Company's 52-week high was at $4.46Company's 52-week low was at $1.75Price action over last quarter: down 12.44%Company Overview Acacia Research Corp is engaged in the acquisition, development, and patents technologies through its subsidiaries. It assists patent owners with the prosecution and development of their patent portfolios; protection of their patented inventions from unauthorized use; generation of licensing revenue from users of their patented technologies; and enforcement against unauthorized users of their patented technologies.See more from Benzinga * Click here for options trades from Benzinga * WhiteHorse Finance: Q3 Earnings Insights * Recap: Hemisphere Media Q3 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Acacia Research Reports Third Quarter 2020 Financial Results
(Mon, 09 Nov 2020 13:20:00 +0000)
Acacia Research Corporation (Nasdaq: ACTG) today reported results for the three-month period ended September 30, 2020.
Acacia Research to Release Third Quarter Financial Results
(Mon, 26 Oct 2020 10:00:00 +0000)
Acacia Research Corporation ("Acacia" or "the Company") (NASDAQ: ACTG) announced today it will release its third quarter financial results on Monday, November 9, 2020 at 8:00 a.m. ET/ 5:00 a.m. PT.
Is Acacia Research (NASDAQ:ACTG) Using Debt In A Risky Way?
(Sun, 25 Oct 2020 12:13:55 +0000)
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
LAB LABRANCHE & CO INC COM
SectorFinancial
RecommendationsBuy
Buy Near6.23
Stop Loss4.72
Posted Date11/2/2008 12:00:00 AM
First resistance7.43
Second resistance7.98
Third resistance11.80
First Support5.70
Second Support4.72
Comments
11/3/2008 12:00:04 AM0) LaBranche & Co Inc.com (LAB)Stocks given a double top breakout on 10/31/08 with good volume again many technical indicators also have given a buy signal, with rising moving average
1) Stockhastic and ADX also given a buy signal
2) LaBranche & Co Inc.com (LAB) is a Stock-exchange specialist firm
3) As per technical analysis and fundamentally LaBranche & Co Inc.com (LAB) look good candidate for portfolio investment. LaBranche & Co Inc.com you can consider for Investment, Swing trading, Stock trading, penny Stock Investing, Day trading
4) Due to market and economic condition keep tight stop loss on all position
5) You can buy LaBranche & Co Inc.com (LAB) near $6.23
LAB


Next Page >>   

 

























Home for ۩ Day Trading | Breakout Stock trading system | Penny Stock Investing | Market Research

Contact Us | Affiliate | Disclaimer | Feedback | Help | Site Map | RSS  RSS
All Rights Reserved © 2000-2006 Flyingstock.com
Penny Stock picks for Stock trading Penny Stock investing support resistance

This Service is solely an information service provided by the automated software tool & is for entertainment purposes only. It should be understood that there is no guarantee that past performance of our stock trading system or day trading Strategy or Penny stock picks will be indicative of future results.